Value through Innovation04 February 2016

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

10.11.2015

Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research

10.11.2015

Boehringer Ingelheim Announces Completed Enrollment of Phase III Clinical Trial for Biosimilar Candidate to Adalimumab

10.11.2015

Real-World Analysis of more than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® in Routine Clinical Care

10.11.2015

Boehringer Ingelheim Presents New idarucizumab (Praxbind®) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran

09.11.2015

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

06.11.2015

EMPA-REG OUTCOME®: Top-line renal data to be presented during American Society of Nephrology (ASN) Kidney Week 2015

06.11.2015

Change in Board of Managing Directors to ensure continuity and focus on the future

03.11.2015

Boehringer Ingelheim initiates pivotal programme for novel third-generation EGFR targeting lung cancer compound

28.10.2015

CHEST: New Sub-Analyses Show Improvement in COPD Patient Outcomes with Spiolto® Respimat®

28.10.2015

Boehringer Ingelheim’s Biosimilar Candidate Demonstrated Pharmacokinetic Bioequivalence to Adalimumab

19.10.2015

FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate)

- For Media outside of the US
15.10.2015

Boehringer Ingelheim Animal Health presents its first live web congress on Bovine Viral Diarrhoea

12.10.2015

Boehringer Ingelheim and Philogen collaborate to investigate novel treatment approaches for Acute Myeloid Leukemia

09.10.2015

Boehringer Ingelheim Animal Health announces winners of the 2015 European PRRS Research Award

08.10.2015

Boehringer Ingelheim’s investigational biologic cleared skin better, faster and for longer than ustekinumab in phase II psoriasis study

08.10.2015

Delayed IPF diagnosis negatively impacts patients by delaying treatment according to global survey of pulmonologists1

29.09.2015

New data demonstrate sustained long-term efficacy of OFEV®* on slowing disease progression and safety in patients with IPF

28.09.2015

COPD: New data support role of Spiolto® Respimat® as 1st-line maintenance therapy and show superiority over LABA/ICS